In phase 2 dose-finding (n=838) and dose-confirmation (n=1051) studies in participants aged ≥50, aQIVc [45,2×] produced superior antibody titres vs QIVc [15,0×] for all strains (GMT ratios 1.27-1.86); solicited adverse events were 71.1% vs 50.4%.
RCTn = 1,889
de Looze et al. Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: Combined results of randomised, controlled dose-finding and dose-confirmation studies